Stocks · News reference
AEON Biopharma Regains NYSE American Compliance
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 8:22 PM
- Checked
- Aug 3, 2026, 8:22 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.6 million. As per the news, the Q2 earnings report came
Read original at benzingaAEON Biopharma Announces Final, Expanded Primary Structure Results And Preliminary Disulfide Bond Characterization Data Providing Complementary Evidence Supporting Molecular Similarity Of ABP-450 To BOTOX
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary
Read original at benzingaHC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2
HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target from $5 to $1.2.
Read original at benzinga